Myasthenia Gravis (MG) functions as a complex autoimmune condition that interferes with neuromuscular junction communication, producing fluctuating muscle weakness and exercise-related fatigue. The global myasthenia gravis pharmaceutical ecosystem demonstrates significant growth momentum, driven by sophisticated diagnostic innovations, increased medical recognition, and evolving therapeutic...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Bangla